ASX · HMD.AX
HeraMED Limited
A$0.04+A$0.00 (+8.82%)
HeraMED Limited’s quoted price sits in the lower half of its reported 52-week range, 32.73% below the high.
Loading market information…
ASX · IDT.AX · AUD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:19 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
IDT Australia Limited’s quoted price sits in the lower half of its reported 52-week range, 29.03% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
IDT Australia Limited’s forward annual dividend is A$0.02 per share, paid semi-annual. The forward yield is 38.13% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
IDT Australia Limited’s next earnings report is currently expected on Feb 23, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow IDT Australia Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and finished dosage forms. The company furnishes comprehensive analytical support, including the establishment of testing methodologies, stability assessments utilizing specialized chambers, and quality control laboratory services for both chemical and microbiological applications. Furthermore, its service offerings span project management, chemical processing, advanced analytical chemistry, pharmacy support, clinical trial packaging, and regulatory compliance assistance, alongside pharmaceutical development expertise across diverse dosage forms. Notably, IDT Australia also provides medicinal cannabis products and a broad array of contract manufacturing solutions. Established in 1975, the firm is headquartered in Boronia, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.04+A$0.00 (+8.82%)
HeraMED Limited’s quoted price sits in the lower half of its reported 52-week range, 32.73% below the high.
A$0.07A$0.00 (0.0%)
Resonance Health Limited’s quoted price sits in the upper half of its reported 52-week range, 13.95% below the high.
A$0.67-A$0.04 (-5.63%)
OncoSil Medical Ltd’s quoted price sits in the lower half of its reported 52-week range, 59.15% below the high.
A$0.06+A$0.00 (0.0%)
Rhythm Biosciences Limited’s quoted price sits in the lower half of its reported 52-week range, 77.5% below the high.
A$0.02-A$0.00 (-4.76%)
Althea Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
A$0.05A$0.00 (0.0%)
Noxopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 55.45% below the high.
A$0.01-A$0.00 (-6.67%)
Atomo Diagnostics Limited’s quoted price sits in the lower half of its reported 52-week range, 70.83% below the high.
A$0.04A$0.00 (0.0%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 59.18% below the high.
